# **Table of Contents**

## State/Territory Name: Mississippi

# State Plan Amendment (SPA) #: 14-011

This file contains the following documents in the order listed:

- 1) RO Follow-Up Approval Letter
- 2) Pharmacy Approval Letter
- 3) CMS 179 Form
- 4) Approved SPA Pages



## DIVISION OF MEDICAID & CHILDREN'S HEALTH OPERATIONS

May 5, 2014

Dr. David J. Dzielak Executive Director Mississippi Division of Medicaid 550 High Street, Suite 1000 Jackson, Mississippi 39201-1399

Attention: Kristi Plotner

RE: Title XIX State Plan Amendment, MS 14-011

Dear Dr. Dzielak:

This is to affirm approval of the above referenced State Plan Amendment which was submitted to the Regional Office on March 17, 2014. The State's requested effective date of January 1, 2014 has been accepted.

Enclosed for your records are:

- 1. a copy of the approval letter dated April 18, 2014 that was submitted to the State by Kim Howard, Acting Director, Division of Pharmacy;
- 2. the original signed 179; and
- 3. the approved plan page.

If you have any additional questions regarding this amendment, please contact Tandra Hodges, State Coordinator for Mississippi at 404-562-7409.

Sincerely,

//s//

Jackie Glaze Associate Regional Administrator Division of Medicaid & Children's Health Operations DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Medicare & Medicaid Services 7500 Security Boulevard, Mail Stop S2-14-26 Baltimore, Maryland 21244-1850



### **Disabled & Elderly Health Programs Group**

April 18, 2014

David J. Dzielak Executive Director Mississippi Division of Medicaid 550 High Street, Suite 1000 Jackson, Mississippi 39201-1399

Attention: Kristi Plotner

Dear Mr. Dzielak:

We have reviewed Mississippi State Plan Amendment (SPA) 2014-011, Prescribed Drugs, received in the Atlanta Regional Office on March 17, 2014. This amendment proposes to remove barbiturates, benzodiazepines, and agents used to promote smoking cessation from the list of drugs the state Medicaid program may exclude from coverage or otherwise restrict in order to comply with the requirements of Section 2502(a) of the Affordable Care Act.

Based on the information provided, we are pleased to inform you that consistent with the regulations at 42 CFR 430.20, Mississippi SPA 2014-011 is approved with an effective date of January 1, 2014. A copy of the signed CMS-179 form, as revised, as well as the pages approved for incorporation into the Mississippi state plan will be forwarded by the Atlanta Regional Office.

If you have any questions regarding this amendment, please contact Bernadette Leeds at (410) 786-9463.

Sincerely,

/s/

Kim Howell Acting Director Division of Pharmacy

cc: Jackie Glaze, ARA, Atlanta Regional Office Caletha Henry, Atlanta Regional Office Judith Clark, Mississippi Division of Medicaid Margaret Wilson, Mississippi Division of Medicaid

	FORM APPROVED OMB NO. 0938-019
NUMBER:	2. STATE
11	MS
TIFICATION: TI	TITLE XIX OF THE DICAID)
4. PROPOSED EFFECTIVE DATE January 1, 2014	
EW PLAN	AMENDMENT
Fransmittal for each	
GET IMPACT:	
OF THE SUPERS	RSEDED PLAN SECTION e):
Exhibit 12a, page	ges 1 and 2
OTHER, AS SPEC	excluded drugs. This
Miss. Division of Medicaid Attn: Kristi Plotner 550 High Street, Suite 1000 Jackson, MS 39201-1399	
l	
ROVED: 04-18-14	4
IED	
E OF REGIONAL	
ociate Regional Ad	dministrator
icaid & Children I	Health Opns

## State of Mississippi

# DESCRIPTIONS OF LIMITATIONS AS TO AMOUNT, DURATION AND SCOPE OF MEDICAL CARE AND SERVICES PROVIDED

### 12a. Prescribed Drugs:

- (1) Covered outpatient drugs are those produced by any manufacturer which has entered into and complies with an agreement under Section 1927 (a) of the Act which are prescribed for a medically acceptable indication. Compounded prescriptions (mixtures of two (2) or more ingredients) except for hyperalimentation are not covered.
- (2) All Medicaid beneficiaries age 21 and older are limited to five (5) prescriptions per month with no more than two (2) brand name (single source or innovator multiple source) drugs per month for each non-institutionalized Medicaid beneficiary.
- (3) As provided in Section 1935 (d) (1) of the Act, effective January 1, 2006, the Medicaid agency will not cover any Part D drug for full-benefit dual eligible under Part A or Part B.
- (4) As provided by Sections 1927 (d)(2) and 1935 (d)(2) of the Act, the Medicaid agency provides coverage for the following excluded or otherwise restricted drugs or classes of drugs, or their medical uses, to all Medicaid beneficiaries including full benefit dual eligible beneficiaries under the Medicare prescription Drug Benefit-Part D.
- (a) Agents when used for anorexia, weight loss or weight gain;
- (b) Agents when used to promote fertility;
  - (c) Agents when used for cosmetic purposes or hair growth;
  - (d) Covered outpatient drugs which the manufacturer seeks to require as a condition of sale that associated tests or monitoring services be purchased exclusively from the manufacturer or its designee;
- (e) Those drugs designated less than effective by the FDA as a result of the Drug Efficacy Study Implementation (DESI) program;
- (f) Nonparticipating rebate manufacturers;
- (g) Select agents when used for symptomatic relief of cough and colds: antihistamines, decongestants, antihistamine/decongestant combination products, legend antitussive benzonate;

П

#### STATE PLAN UNDER TITLE XIX OF THE SOCIAL SECURITY ACT

### MEDICAL ASSISTANCE PROGRAM

## State of Mississippi

 $\boxtimes$ 

(h) Select prescription vitamins and mineral products, except prenatal vitamins and fluoride:

vitamin K, cyanocobalamin injection, vitamin D, folic acid as a single entity;

 Select nonprescription (OTC) drugs: Insulin, allergy and sinus products, analgesics/antipyretics, antitussives, antitussive/expectorants, digestive medications, ophthalmic agents, topical antibiotics, topical antiparasitics, topical antifungals, and vaginal antifungals.